Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy
- 1 December 1992
- journal article
- research article
- Published by Springer Nature in Calcified Tissue International
- Vol. 51 (6) , 419-423
- https://doi.org/10.1007/bf00296674
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Dose of bisphosphonate for hypercalcaemia of malignancyThe Lancet, 1990
- Chronic high-dose pamidronate in refractory malignant hypercalcaemiaThe Lancet, 1990
- RENAL PHOSPHATE THRESHOLD AND RESPONSE TO PAMIDRONATE IN HUMORAL HYPERCALCAEMIA OF MALIGNANCYThe Lancet, 1989
- Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.Journal of Clinical Investigation, 1989
- A Parathyroid Hormone-Related Protein Implicated in Malignant Hypercalcemia: Cloning and ExpressionScience, 1987
- Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.BMJ, 1986
- COMPARISON OF AMINOHYDROXYPROPYLIDENE DIPHOSPHONATE, MITHRAMYCIN, AND CORTICOSTEROIDSICALCITONIN IN TREATMENT OF CANCER-ASSOCIATED HYPERCALCAEMIAThe Lancet, 1985
- HYPERCALCAEMIA AND METASTATIC BONE DISEASE: IS THERE A CAUSAL LINK?The Lancet, 1982
- Biochemical Evaluation of Patients with Cancer-Associated HypercalcemiaNew England Journal of Medicine, 1980
- Nephrogenous Cyclic Adenosine Monophosphate as a Parathyroid Function TestJournal of Clinical Investigation, 1977